Treatment Patterns and Prognostic Nomograms for Overall Survival and Hepatic Progression-Free Survival in Unresectable Colorectal Liver Metastases Treated with Drug-Eluting Bead Chemoembolization: A Single-Center Study
Current Oncology · 2026
DOI: 10.3390/curroncol33090497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Ketong Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Chemoembolization, Therapeutic, Colorectal Neoplasms, Nomograms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Drug-eluting bead transarterial chemoembolization (DEB-TACE) is increasingly used for unresectable colorectal liver metastases (CRLM), yet individualized prognostic tools are lacking. We developed and internally validated nomograms predicting overall survival (OS) and hepatic progression-free survival (hPFS). (2)
Methods
In this single-center retrospective cohort, reported per the TRIPOD guideline, OS and hPFS were estimated by Kaplan–Meier methods, and independent predictors from multivariable Cox regression were assembled into nomograms. Internal validation combined 1000-sample bootstrap optimism-corrected concordance indices (C-index), a uniform shrinkage factor, a bootstrap calibration slope, and a LASSO–Cox sensitivity analysis. (3)
Results
Among 63 patients (44 deaths; 42 intrahepatic-progression events), median OS was 10.9 months and median hPFS was 5.8 months. Independent OS predictors were baseline CEA, high liver tumor burden (≥10 lesions), CEA decline (protective), and second-line-or-beyond interventional therapy (corrected C-index: 0.796). Independent hPFS predictors were high liver tumor burden, CEA decline, and age (corrected C-index: 0.718). Nomogram-defined high-risk groups had markedly shorter OS (5.3 vs. 22.8 months) and hPFS (3.3 vs. 8.6 months; both p < 0.001). Grade ≥3 toxicity occurred in 6%. (4)
Conclusions
In real-world DEB-TACE-treated CRLM, liver tumor burden and CEA dynamics dominated prognosis; the internally validated nomograms provide individualized estimates and risk stratification, pending external validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
- Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
- Department of Radiotherapy, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
ORCID-Profile: Weiyao Li
Zitieren
APA
Wu, K., Chen, H., Li, D., Wan, Y., Li, W., & Zhang, B. (2026). Treatment Patterns and Prognostic Nomograms for Overall Survival and Hepatic Progression-Free Survival in Unresectable Colorectal Liver Metastases Treated with Drug-Eluting Bead Chemoembolization: A Single-Center Study. Current Oncology. https://doi.org/10.3390/curroncol33090497
Vancouver
Wu K, Chen H, Li D, Wan Y, Li W, Zhang B. Treatment Patterns and Prognostic Nomograms for Overall Survival and Hepatic Progression-Free Survival in Unresectable Colorectal Liver Metastases Treated with Drug-Eluting Bead Chemoembolization: A Single-Center Study. Current Oncology. 2026. doi:10.3390/curroncol33090497
BibTeX
@article{Wu2026,
author = {Wu, Ketong and Chen, Haiyang and Li, Dan and Wan, Yuan and Li, Weiyao and Zhang, Bo},
title = {Treatment Patterns and Prognostic Nomograms for Overall Survival and Hepatic Progression-Free Survival in Unresectable Colorectal Liver Metastases Treated with Drug-Eluting Bead Chemoembolization: A Single-Center Study},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33090497}
}
EUVIMED